On February 27, 2025, Michael Labarre, Senior Vice President and Chief Technical Officer at Halozyme Therapeutics Inc (HALO, Financial), executed a sale of 21,697 shares of the company. Following this transaction, the insider now holds 173,756 shares of the company. The details of this transaction can be found in the SEC Filing. Halozyme Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative products that target the extracellular matrix for the treatment of cancer, diabetes, and other diseases. The company utilizes its proprietary enzyme technology to enhance the delivery of biologics and small molecules. Over the past year, Michael Labarre has sold a total of 191,697 shares and has not made any purchases. The insider transaction history for Halozyme Therapeutics Inc indicates that there have been no insider buys in the past year, while there have been 20 insider sells. On the day of the recent sale, shares of Halozyme Therapeutics Inc were trading at $58.10, giving the stock a market cap of $7.11 billion. The company's price-earnings ratio stands at 16.82, which is lower than the industry median of 29.26 and also lower than the company's historical median price-earnings ratio. With a trading price of $58.10 and a GF Value of $64.07, Halozyme Therapeutics Inc has a price-to-GF-Value ratio of 0.91, indicating that the stock is modestly undervalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company's past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
